| 李锦华,王雪梅,郑 洁,刘蜀敏,邹 艳,岳梦青,易红莉.玉屏风颗粒联合重组人干扰素α-1b雾化吸入治疗对反复呼吸道感染患儿炎性因子和T细胞亚群的影响[J].,2021,(5):894-897 |
| 玉屏风颗粒联合重组人干扰素α-1b雾化吸入治疗对反复呼吸道感染患儿炎性因子和T细胞亚群的影响 |
| The Effect of Yupingfeng Granules Combined with Recombinant Human Interferon α-1b Aerosol Inhalation on Inflammatory Factors and T Cell Subsets in Children with Recurrent Respiratory Tract Infection |
| 投稿时间：2020-08-08 修订日期：2020-08-30 |
| DOI：10.13241/j.cnki.pmb.2021.05.019 |
| 中文关键词: 玉屏风颗粒 重组人干扰素α-1b 雾化吸入 反复呼吸道感染 炎性因子 T细胞亚群 |
| 英文关键词: Yupingfeng granules Recombinant human interferon α-1b Aerosol inhalation Recurrent respiratory tract infection Inflammatory factors T cell subsets |
| 基金项目:重庆市卫计委高端人才后备项目(2015HBRC0010) |
|
| 摘要点击次数: 904 |
| 全文下载次数: 507 |
| 中文摘要: |
| 摘要 目的：探讨在重组人干扰素α-1b雾化吸入治疗的基础上加用玉屏风颗粒对反复呼吸道感染（RRTI）患儿炎性因子和T细胞亚群的影响。方法：将我院于2018年3月~2020年2月期间收治的RRTI患儿180例根据信封抽签法分为对照组（n=90）和实验组（n=90），均给予止咳、退热、平喘、抗感染等常规治疗的基础上，对照组患儿予以重组人干扰素α-1b雾化吸入治疗，实验组患儿则在对照组的基础上联合玉屏风颗粒治疗，比较两组患儿疗效、症状消失时间、炎性因子、T细胞亚群和不良反应。结果：实验组治疗3周后的临床总有效率为91.11%（82/90）高于对照组的78.89%（71/90）（P<0.05）。实验组肺部啰音、发热、喘息、咳嗽症状消失时间较对照组短（P<0.05）。两组治疗3周后血清白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、白介素-10（IL-10）水平均下降，且实验组低于对照组（P<0.05）。两组治疗3周后CD8+较治疗前降低，且实验组低于对照组（P<0.05）；CD4+/CD8+、CD3+、CD4+均较治疗前升高，且实验组高于对照组（P<0.05）。比较两组不良反应发生率未见统计学差异（P>0.05）。结论：玉屏风颗粒联合重组人干扰素α-1b雾化吸入治疗RRTI患儿，可迅速改善患儿临床症状、T细胞亚群以及炎性因子水平，且不增加不良反应发生率，疗效令人满意。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Yupingfeng granules combined with recombinant human interferon α-1b aerosol inhalation on inflammatory factors and T cell subsets in children with recurrent respiratory tract infection (RRTI). Methods: 180 children with RRTI who were admitted to our hospital from March 2018 to February 2020 were selected, children were divided into control group (n=90) and experimental group (n=90) according to the envelope lottery method. On the basis of routine treatment such as cough relief, antipyretic, antiasthmatic and anti infection, the children in the control group were treated with recombinant human interferon α-1b aerosol inhalation. The children in the experimental group were treated with Yupingfeng granules on the basis of the control group. The curative effect, symptom disappearance time and inflammation factors, T cell subsets and adverse reactions of the two groups were compared. Results: The total clinical effective rate of the experimental group was 91.11%(82/90) at 3 weeks after treatment was higher than that 78.89%(71/90) of the control group (P<0.05). The disappearance time of lung rale, fever, wheeze, and cough of the experimental group were shorter than those of the control group (P<0.05). The levels of serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) in two groups at 3 weeks after treatment decreased, and the levels of the experimental group were lower than those of the control group (P<0.05). CD8+ decreased compared with that before treatment, and that in the experimental group was lower than that in the control group (P<0.05). CD4+/CD8+, CD3+, CD4+ in two groups at 3 weeks after treatment increased, and the experimental group was higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Yupingfeng granules combined with recombinant human interferon α-1b aerosol inhalation in treatment of children with RRTI, which can rapidly improve the clinical symptoms, T cell subsets and inflammatory factors levels, and does not increase the incidence of adverse reactions, and the efficacy is satisfactory. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
